Skip to Content

'
Dennis P. Hughes, M.D., Ph.D.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Division of Pediatrics, University of Texas M.D. Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Graduate Faculty, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX

Education & Training

Postgraduate Training

2/2003-8/2004 Lecturer/Research Fellow, Sarcoma Correlative Sciences Laboratories, Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI
7/2000-1/2003 Research Fellow, Retroviral/Genetic Immunotherapy, Tumor Immunity Program, University of Michigan, Ann Arbor, MI
7/1999-6/2002 Fellowship, Pediatric Hematology/Oncology, University of Michigan Medical Center, Ann Arbor, MI
7/1997-6/1999 Residency, Pediatrics, University of Vermont - Fletcher Allen, Burlington, VT
6/1996-6/1997 Internship, Pediatrics, University of Vermont - Fletcher Allen, Burlington, VT

Experience/Service

Administrative Appointments/Responsibilities

Co-Director, MD-PhD Program, University of Texas Health Science Center at Houston, Houston, TX, 7/2007-present

Institutional Committee Activities

Member, Institutional Research Grants Study Section, 2007-present
Member, Advisory Board, The Jori Zemel Children's Bone Cancer Foundation, Clear Lake, Texas, 1/2005-present

Professional Memberships

American Association for Cancer Research
Member, 2003-present
American Society of Clinical Oncology
Member, 2001-present
American Society of Pediatric Hematology/Oncology
Member, 2002-present
Children's Oncology Group
Associate Member, 2002-present
Connective Tissue Oncology Society
Member, 2004-present

Selected Publications

Peer-Reviewed Original Research Articles
1. Geryk-Hall M, Hughes DPM. Critical Signaling Pathways in Bone Sarcoma: Candidates for Therapeutic Intervention. Curr Onc Reports. In Press.
2. Dennis P. M. Hughes. Strategies for the targeted delivery of therapeutics for Osteosarcoma. Expert Opinion on Drug Delivery. In Press.
3. Nikolova DA, Asangani IA, Nelson LD, Hughes DPM, Siwak D, Mills GB, Harms A, Buchholz E, Pilz L, Manegold C, Allgayer H. Cetuximab attenuates invasion, metastasis, and u-PAR gene expression in non small-cell lung cancer (NSCLC), and u-PAR, besides E-cadherin, is a novel biomarker of Cetuximab sensitivity. Cancer Research 69(6):2461-70, 2009. PMID: 19276367.
4. Hughes DPM. Novel agents in development for pediatric sarcomas. Curr Opin Oncol 21(4):332-7, 2009. PMID: 19444103.
5. Anderson P, Kornguth D, Ahrar K, Hughes D, Phan P, Huh W, Cornelius K, Mahajan A. Recurrent, Refractory, Metastatic, and/or Unresectale Pediatric Sarcomas: Treatment Options for Young People that are "Off the Roadmap". Pediatric Health 2(5):605-615, 10/2008.
6. Zhang P, Yang Y, Zweidler-McKay PA, Hughes DPM. A critical role of Notch signaling in osteosarcoma invasion and metastasis. Clinical Cancer Research 14(10):2962-2969, 5/2008.
7. Mahajan A, Woo, SY, Kornguth DG, Hughes D, Huh W, Chang EL, Herzog C, Pelloski CE, Anderson P. Multimodality treatment of osteosarcoma: radiation in a high-risk cohort. Pediatric Blood & Cancer 50:976-982, 1/2008.
8. Li S, Yang J, Urban FA, MacGregor JN, Hughes DP, Chang AE, McDonagh KT, Li Q. Genetically engineered T cells expressing a HER2-specific chimeric receptor mediate antigen-specific tumor regression. Cancer Gene Ther 15(6):382-392, 2008. PMID: 18292797.
9. Mensah-Osman EJ, Thomas DG, Tabb MM, Larios JM, Hughes DP, Giordano TJ, Lizyness ML, Rae JM, Blumberg B, Hollenberg PF, Baker LH. Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer 109:957-65, 2007. PMID: 17279585.
10. Lemme S, Raymond A, Cannon C, Normand A, Smith K, Hughes DPM. Primary tuberculosis of bone mimicking a lytic bone tumor. JPHO 29(3):198-202, 2007.
11. Hughes DPM, Thomas DG, Giordano TJ, McDonagh KT, Baker LH. Essential erbB family phosphorylation in osteosarcoma as a target for CI-1033 inhibition. Pediatr Blood Cancer 46:614-623 2006 Published Online: 8 Jul 2005, 2006. PMID: 16007579.
12. Macgregor JN, Li Q, Chang AE, Braun TM, Hughes DPM, McDonagh KT. Ex vivo culture with interleukin (IL)-12 improves CD8(+) T-cell adoptive immunotherapy for murine leukemia independent of IL-18 or IFN-gamma but requires perforin. Cancer Res 66:4913-4921, 2006. PMID: 16651448.
13. Hughes DPM. Protein lysate array assessment of therapeutic targets in sarcoma. European Journal of Cancer 4(6):24, 2006.
14. Hughes DPM, Baskar D, Urban FF, Friedman MS, Braun TM, McDonagh KT. Fate and function of anti-CD3/CD28-activated T cells following adoptive transfer: IL-2 promotes development of anti-tumor memory T cells in vivo. Cytotherapy 7(5):396-407, 2005. PMID: 16236629.
15. Li SP, Urban FA, Macgregor JN, Hughes DP, McDonagh KT. [Chimeric T cell receptor N29gamma redirect T lymphocytes response specific to p185HER2 in A murine model of metastatic breast cancer]. Ai Zheng 23(11 Suppl):1370-5, 11/2004. PMID: 15566639.
16. Hughes DPM, Thomas DG, Giordano TJ, Baker LH, McDonagh KT. Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res 64(6):2047-2053, 2004. PMID: 15026342.
17. Hong R, Shen V, Rooney C, Hughes DPM, Smith C, Comoli P, Zhang L. Correction of DiGeorge anomaly with EBV-induced lymphoma by transplantation of organ-cultured thymus and Epstein-Barr-specific cytotoxic T lymphocytes. Clin Immunol 98(1):54-61, 2001. PMID: 11141327.
18. Peng SL, Madaio MP, Hughes DPM, Crispe IN, Owen MJ, Wen L, Hayday AC, Craft J. Murine lupus in the absence of alpha beta T cells. J Immunol 156:4041-4049, 1996. PMID: 8621947.
19. Hughes DPM, Crispe IN. A naturally occurring soluble isoform of murine Fas generated by alternative splicing. J Exp Med 182(5):1395-1401, 1995. PMCID: PMC2192224.
20. Hughes DPM, Hayday A, Craft JE, Owen MJ, Crispe IN. T cells with gamma/delta T cell receptors (TCR) of intestinal type are preferentially expanded in TCR-alpha-deficient lpr mice. J Exp Med 182(1):233-241, 1995. PMCID: PMC2192080.

Invited Articles
1. Anderson P, Kopp L, Anderson N, Cornelius K, Herzog C, Hughes D, Huh W. Novel Bone Cancer Drugs: Investigational Agents and Control Paradigms for Bone Sarcomas. Expert Opinion on Investigational Drugs 17(11):1703-15, 2008. PMID: 18922107.

Book Chapters
1. Hughes DPM. How the NOTCH Pathway Contributes to the Ability of Osteosarcoma Cells to Metastasize. In: Pediatric and Adolescent Osteosarcoma, Cancer Treatment and Research Series. Ed(s) N Jaffe, et al. Springer Science and Business Media, LLC: Berlin, Germany. In Press.
2. Hughes DPM, Levine J. Immunotherapeutic approaches to the HSCT patient. In: Pediatric Bone Marrow Transplantation Kline RM (ed). Marcel Dekker, Inc. New York, 2005.
3. Hughes DPM, Levine J. Immunotherapy options for relapse after BMT. In: Pediatric Stem Cell Transplantation. Mehta P (ed), Janes and Bartlett Publishers, Inc. Sudbury, MA, 2003.

Grant & Contract Support

Title: Pharmacological and Genetic Blockade of Hes1 in Osteosarcoma Suppresses Invasiveness and Metastasis In Vitro and In Vivo
Funding Source: Hope Street Kids Fellowship
Role: Principal Investigator
Duration: 7/1/2007 - 6/30/2009
 
Title: Physicians Scientist Award
Funding Source: University of Texas M.D. Anderson Cancer Center
Role: Principal Investigator
Duration: 4/1/2007 - 5/31/2010
 
Title: Ras-mediated erbB Signaling in Osteosarcoma
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/24/2006 - 5/31/2011
 
Funding Source: Jori Zemel Children's Bone Cancer Foundation: Zemel Scholar Award
Role: Mentor of Scholars
Duration: 12/1/2005 - present
 
Funding Source: Mike Doiron Legends of Friendswood Foundation
Role: Principal Investigator
Duration: 10/1/2005 - 9/30/2006
 
Title: Antigenic threshold for a Her-2-specific chimeric TCR
Funding Source: Children's Health Research Center Grant, University of Michigan, Department of Pediatric,
Role: Principal Investigator
Duration: 9/1/2003 - 8/31/2004
 
Title: Adoptive Immunotherapy for GD2-expressing Osteosarcoma
Funding Source: Translational Research Program of the Group Chair's Development Fund
Role: Principal Investigator
Duration: 2/1/2003 - 11/30/2003
 
Title: Adoptive Immunotherapy for GD2-expressing Osteosarcoma
Funding Source: John and Suzanne Munn Research Grant
Role: Principal Investigator
Duration: 1/1/2003 - 1/1/2004
 
Title: Research Award, Evan Shapiro Fund to Combat Pediatric Cancer, Her-2 and EGFR family member expression in pediatric sarcomas
Funding Source: University of Michigan Comprehensive Cancer Center
Role: Co-Investigator
Principal Investigator: Gregory Yanik
Duration: 7/1/2002 - 8/31/2004
 
Title: Genetic immunotherapy for malignancy: murine modeling
Funding Source: National Institutes of Health, Individual NRSA Training Award National Institutes of Health
Role: Principal Investigator
Duration: 7/1/2002 - 6/30/2004

Last updated: 9/25/2009